Healthcare Stakeholders Pushing for Pharmacogenomics to Guide Comparative Effectiveness Reviews

Industry stakeholders and patient advocates are urging the government to ensure that any resulting comparative effectiveness program not focus solely on reducing cost but on using pharmacogenomics to improve patient outcomes.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.